The Role of the Endocannabinoid System in Sweet Taste Intensity and Liking (NCT02112292) | Clinical Trial Compass
CompletedNot Applicable
The Role of the Endocannabinoid System in Sweet Taste Intensity and Liking
Netherlands10 participantsStarted 2014-04
Plain-language summary
The endocannabinoid (eCB) system, a neurochemical signalling system consisting of CB-receptors and their endogenous ligands, has been found to be involved in food intake of sweet and palatable foods. Activation of the eCB system increases food intake and vice versa. The mechanism behind this effect is still unknown and the current study aims at clarifying why sweet food intake increases. It is hypothesized that sweet taste intensity increases and that sweet taste is experienced as more pleasant.
Who can participate
Age range
18 Years – 35 Years
Sex
MALE
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* BMI: 18.5 - 25 kg/m2
* Incidental cannabis use for at least one year, at least four times per year, but less than once a week.
* Dutch-speaking
* Willing to comply with the study procedures
* Having given written informed consent
Exclusion Criteria:
* Not meeting the inclusion criteria
* Restraint eating (men: score \> 2.90)
* Lack of appetite
* Having difficulties with swallowing/eating
* Usage of an energy restricted diet during the last two months
* Weight loss or weight gain of 5kg or more during the last two months
* Stomach or bowel disease
* Diabetes, thyroid disease, other endocrine disorders
* Use of daily medication except paracetamol
* Having taste or smell disorders (self-report)
* Being allergic/intolerant for products under study
* Previously experienced an adverse reaction to cannabinoids (e.g. anxiety, paranoia, nausea)
* Having (had) a schizophrenia or other psychotic illness
* Having a family history of schizophrenia or other psychotic illness
* Working at the Division of Human Nutrition (WUR)
* Current participation in other research from the Division of Human Nutrition (WUR)
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.